Plain-English translation of NCT07446452 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether disitamab vedotin combined with can help treat advanced breast cancer that has spread and stopped responding to a previous drug called T-DXd. Both medications are given as infusions every two weeks. The study will measure how well this combination works and what side effects patients experience.
Some patients with HER2-low breast cancer (a specific type based on protein levels) don't benefit from standard treatments or their cancer comes back even after receiving T-DXd therapy. This trial aims to find a new treatment option for these patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly to receive two intravenous (IV) infusions every two weeks—one of each medication. The trial continues until your cancer progresses, you experience unacceptable side effects, or you choose to withdraw. Doctors will monitor you closely with blood tests, imaging scans, and heart function checks, and you'll answer questions about how you're feeling and your quality of life at certain visits.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China